Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | GHSR | Q92847 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.65 |
| ▸ | DRD1 | P21728 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 3/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buclizine SCHEMBL22171621 | 1.00 | KCNH2 (1.00) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL123752 | 1.00 | KCNH2 (1.00) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL123751 | 0.99 | KCNH2 (0.98) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL123753 | 0.99 | KCNH2 (0.98) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL10769522 | 0.90 | CYP3A4 (0.84) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL12464946 | 0.89 | KCNH2 (0.80) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL3611802 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL588110 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL588111 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| Hydrochloric Acid SCHEMBL588128 | 0.85 | LMNA (0.79) | KCNH2LMNAADORA3CNR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6184 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12569451-B2 | Bio-inspired tissue-adhesive hydrogel patch and uses thereof | Cellartgen Inc. (KR) | 2026-03-10 | — | — | US | claimed |
| EP-4691492-A2 | LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-12263168-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-04-01 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-12251469-B2 | Sterically stabilized carrier compositions for treating a mammal | VGSK TECHNOLOGIES, INC. (US) | 2025-03-18 | — | — | US | claimed |
| WO-1999001133-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION, COMPRISING AN ACTIVE SUBSTANCE AND A CYCLODEXTRIN | UCB, S.A. (BE) | 1999-01-14 | — | — | WO | claimed |
| WO-1998052540-A1 | PHARMACEUTICAL COMPOSITIONS | THE BOOTS COMPANY PLC (GB) | 1998-11-26 | — | — | WO | claimed |
| WO-1998052545-A1 | PHARMACEUTICAL COMPOSITIONS OF FLURBIPROFEN AND BURN-MASKING AGENT FOR TREATING SORE THROAT | THE BOOTS COMPANY PLC (GB) | 1998-11-26 | — | — | WO | claimed |
| EP-0617028-A1 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine | U C B, S.A. (BE) | 1994-09-28 | — | — | EP | claimed |
| EP-0201537-B1 | NOVEL USE OF ANTI-NAUSEA AND ANTI-EMETIC PHARMAZEUTICAL AGENTS. | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| US-4729997-A | ANTIEMETICS, ANTIHISTAMINES | NASTECH PHARMACEUTICAL CO., INC. (US) | 1988-03-08 | — | — | US | claimed |
| EP-0201537-A4 | NOVEL USE OF ANTI-NAUSEA AND ANTI-EMETIC PHARMAZEUTICAL AGENTS. | NASTECH PHARM CO (US) | 1987-07-06 | — | — | EP | claimed |
| EP-0201537-A1 | NOVEL USE OF ANTI-NAUSEA AND ANTI-EMETIC PHARMAZEUTICAL AGENTS. | NASTECH PHARM CO (US) | 1986-11-20 | — | — | EP | claimed |
| WO-1986002553-A1 | NOVEL METHOD OF ADMINISTERING ANTI-NAUSEA AND ANTI-EMETIC PHARMACEUTICAL AGENTS AND NOVEL DOSAGE FORMS CONTAINING SAME | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 1986-05-09 | — | — | WO | claimed |
| US-3940485-A | Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds | LEVINSON HAROLD N | 1976-02-24 | — | — | US | claimed |